Panellists in this video:
+ Mr Subba Reddy Arumalla, Associate VP – Cluster Head API Plant Management, Amneal Pharmaceuticals (Moderator)
+ Dr T Pavan Pradeep, CEO, Actimus Biosciences
+ Mr K V Sreenivasa Babu, VP-Operations, Natco Pharma
+ Mr Naimish Mishra, Site Quality Assurance Head-FTO11, Dr Reddy’s Laboratories
Key Highlights:
[1] Vizag must transition from a manufacturing base to an R&D-led, end-to-end drug development hub.
[2] Regulatory delays, infrastructure gaps and process inefficiencies must be fixed to unlock growth.
[3] Building a strong talent pipeline through skill development and industry–academia collaboration is critical.
[4] Vizag’s land availability is a strategic advantage to create integrated, globally competitive pharma clusters.
[5] Sustainability, technology adoption, quality and compliance will ultimately define Vizag’s long-term success as a pharma hub.